Skip Navigation


JAC Advance Access originally published online on January 6, 2003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
51/2/391    most recent
dkg061v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (15)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Nathwani, D.
Right arrow Articles by Davey, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nathwani, D.
Right arrow Articles by Davey, P.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2003) 51, 391-396
© 2003 The British Society for Antimicrobial Chemotherapy

Cost-minimization analysis and audit of antibiotic management of bone and joint infections with ambulatory teicoplanin, in-patient care or outpatient oral linezolid therapy

Dilip Nathwani1,*, Gavin D. Barlow1, Katherine Ajdukiewicz1, Kirsteen Gray2, John Morrison1, Ben Clift3, Anthony J. France1 and Peter Davey1

1 Infection and Immunodeficiency Unit, Ward 42, East Block, 2 Pharmacy and 3 Orthopaedic Infection Unit, Ninewells Hospital and Medical School, Tayside University Hospitals NHS Trust (TUHT), Dundee, UK

Received 4 July 2002; returned 11 September 2002; revised 19 October 2002; accepted 27 October 2002

Bone and joint infections are significant causes of morbidity, mortality and healthcare costs. The cost of treatment for such infections is driven primarily by the length of hospital stay. Many of these infections will require treatment with prolonged periods of parenteral antibiotic therapy. Clinicians and healthcare managers are being attracted increasingly by administering treatment in the ambulatory setting as this offers clinical, economic and quality of life advantages from both the hospital’s and patient’s perspective. Our retrospective audit of managing 55 treatment episodes of bone and joint infections with teicoplanin delivered in the outpatient or home setting revealed that the mean cost of care per episode of infection was less with treatment in the ambulatory setting (£1749.15) compared with the in-patient setting (£11 400) or compared with the hypothetical situation of treatment with oral linezolid in the home setting (£2546). Teicoplanin therapeutic drug monitoring appears to be valuable in establishing optimal serum levels, which appear to correlate with good clinical outcomes. The potential for alternative day or thrice weekly dosing with teicoplanin may offer further cost advantages whilst maintaining equivalent clinical effectiveness.

Keywords: teicoplanin, linezolid, bone and joint infection, therapeutic drug monitoring, cost minimization

* Corresponding author. Tel: +44-1382-660111; Fax: +44-1382-496547; E-mail: dilip.nathwani{at}tuht.scot.nhs.uk


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J Antimicrob ChemotherHome page
J. R. Samuel and F. K. Gould
Prosthetic joint infections: single versus combination therapy
J. Antimicrob. Chemother., January 1, 2010; 65(1): 18 - 23.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
A. L. N. Chapman, S. Dixon, D. Andrews, P. J. Lillie, R. Bazaz, and J. D. Patchett
Clinical efficacy and cost-effectiveness of outpatient parenteral antibiotic therapy (OPAT): a UK perspective
J. Antimicrob. Chemother., December 1, 2009; 64(6): 1316 - 1324.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
J. Hitchcock, A. P. Jepson, J. Main, and H. J. Wickens
Establishment of an outpatient and home parenteral antimicrobial therapy service at a London teaching hospital: a case series
J. Antimicrob. Chemother., September 1, 2009; 64(3): 630 - 634.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
D. Nathwani
Developments in outpatient parenteral antimicrobial therapy (OPAT) for Gram-positive infections in Europe, and the potential impact of daptomycin
J. Antimicrob. Chemother., September 1, 2009; 64(3): 447 - 453.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
E. Lamont, R. A. Seaton, M. Macpherson, L. Semple, E. Bell, and A. H. Thomson
Development of teicoplanin dosage guidelines for patients treated within an outpatient parenteral antibiotic therapy (OPAT) programme
J. Antimicrob. Chemother., July 1, 2009; 64(1): 181 - 187.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
K. Miller, A. J. O'Neill, M. H. Wilcox, E. Ingham, and I. Chopra
Delayed Development of Linezolid Resistance in Staphylococcus aureus following Exposure to Low Levels of Antimicrobial Agents
Antimicrob. Agents Chemother., June 1, 2008; 52(6): 1940 - 1944.
[Abstract] [Full Text] [PDF]


Home page
Journal of Research in NursingHome page
A. Cowie
The dynamic effect on nursing of a changing health service: A Scottish perspective
Journal of Research in Nursing, January 1, 2005; 10(1): 27 - 44.
[Abstract] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.